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Abstract
Clostridium difficile infection (CDI) is costly. Current guidelines recommend metronidazole as first-line therapy and vancomycin as an
alternative. Recurrence is common. Faecal microbiota transplantation (FMT) is an effective therapy for recurrent CDI (RCDI). This study
explores the cost-effectiveness of FMT, vancomycin and metronidazole for initial CDI. We constructed a decision-analytic computer
simulation using inputs from published literature to compare FMT with a 10–14-day course of oral metronidazole or vancomycin for initial
CDI. Parameters included cure rates (baseline value (range)) for metronidazole (80% (65–85%)), vancomycin (90% (88–92%)) and FMT(91%
(83–100%)). Direct costs of metronidazole, vancomycin and FMT, adjusted to 2011 dollars, were $57 ($43–72), $1347 ($1195–1499) and
$1086 ($815–1358), respectively. Our effectiveness measure was quality-adjusted life years (QALYs). One-way and probabilistic sensitivity
analyses were conducted from the third-party payer perspective. Analysis using baseline values showed that FMT($1669, 0.242 QALYs)
dominated (i.e. was less costly and more effective) vancomycin ($1890, 0.241 QALYs). FMT was more costly and more effective than
metronidazole ($1167, 0.238 QALYs), yielding an incremental cost-effectiveness ratio (ICER) of $124 964/QALY. One-way sensitivity
analyses showed that metronidazole dominated both strategies if its probability of cure were >90%; FMT dominated if it cost <$584. In a
probabilistic sensitivity analysis at a willingness-to-pay threshold of $100 000/QALY, metronidazole was favoured in 55% of model
iterations; FMT was favoured in 38%. Metronidazole, as the first-line treatment for CDIs, is less costly. FMT and vancomycin are more
effective. However, FMT is less likely to be economically favourable, and vancomycin is unlikely to be favourable as first-line therapy when
compared with FMT.
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Introduction
The incidence of Clostridium difficile infection (CDI) has steadily
risen since 2000 in the United States, Canada and Europe [1–
4]. These infections place a substantial burden on the US
healthcare system, with estimated costs well over $3 billion
annually [5–8].
Current guidelines recommend metronidazole as the typical
first-line therapy of CDI [5,9]. Vancomycin is recommended as
first-line therapy when a patient is unable to take metronida-
zole, if there is lack of improvement in 5–7 days with
metronidazole, and in severe or fulminant colitis [5].
Unfortunately, recurrent Clostridium difficile infection (RCDI),
defined as subsequent appearance of CDI symptoms after
successful treatment of CDI with appropriate therapy, occurs
in up to 20–30% of patients after an initial infection [10,11].
RCDI can be costly and may have a substantial effect on
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patients’ quality of life [5]. Appropriate treatment of initial CDI
could reduce the likelihood of RCDI.
Vancomycin, most often prescribed as a pulsed or tapered
regimen, is the current standard of care in treating RCDI [5].
However, evidence supporting its effectiveness is mixed, and
no data for guidance on specific dosing and duration exist.
Vancomycin is expensive and has a high rate of RCDI
regardless of the dose, duration or regimen (e.g. pulse or
tapered) prescribed [5,10–13].
Recently proposed guidelines from the American College of
Gastroenterology (ACG) and American Gastroenterology
Association (AGA) include faecal microbiota transplantation
(FMT) as a therapeutic option for RCDI after two or more
recurrences [5,14]. FMT consists of transplanting a faecal
suspension from a healthy donor into the RCDI patient’s
gastrointestinal tract. While an enema is a common transplan-
tation method, alternative routes include nasoenteral (naso-
gastric or nasojejunal) tubes and colonoscopy [15,16]. Though
no randomized controlled trials have been conducted to
determine the efficacy of FMT in treating RCDI, the sparse
published literature on this new technique suggests that rates
of cure with FMT are favourable, with minimal adverse effects
[5,14,15,17–23]. In addition, one recent economic analysis
demonstrated FMT as cost-effective in the context of RCDI
[24]. No studies, however, have evaluated FMT as an initial
therapeutic option for treating the first occurrence of CDI.
The aim of this study is to estimate the cost-effectiveness of
FMT vs. either vancomycin or metronidazole as therapeutic
options for initial CDI. This information will be relevant for
healthcare providers as they decide between therapeutic
options for patients with initial CDI. In addition, payers will
find these results useful as they consider reimbursement for
FMT for initial CDI.
Methods
We constructed a decision-analytic computer simulation
model using TreeAge Pro 2014 (TreeAge Software, Williams-
town, Massachusetts, USA) to compare a 10–14-day course of
oral metronidazole or vancomycin with FMT for initial CDI
from the third-party payer perspective. Our model inputs
were based on the published literature, which included clinical
studies, systematic reviews and other cost-effectiveness
analyses [11,14,15,18,21,25–34].
To investigate the clinical impact of FMT, we incorporated
data from a multicentre long-term follow-up study that
evaluated FMT for RCDI using a colonoscopic approach [18].
Currently there are no published data to evaluate the
effectiveness of FMT for initial CDI. Therefore, we made the
assumption that FMT would be as effective for initial CDI as it
is for RCDI. Simulated patients were followed for 90 days. The
effectiveness outcome from our model was quality-adjusted
life years (QALYs), which is commonly used in the economic
evaluation literature and incorporates both duration and
quality of life. QALYs are constructed by applying utility
weights, which typically range from 0 (death) to 1 (perfect
health), for certain health states to the duration of time in
those health states [35].
Model design
Our model is shown in Fig. 1. Patients enter the model once a
diagnosis of CDI is made. We assumed that patients entering
the model were adults receiving outpatient treatment.
Patients entering the model could be treated with either a
10–14-day course of oral metronidazole or vancomycin or
FMT. We assumed that metronidazole was given as 500 mg by
mouth three times daily and vancomycin was given as 125 mg
by mouth four times daily [5,10–13]. For FMT, we assumed
that donor stool was administered via colonoscopy. This is the
same protocol used in the only multicentre long-term
follow-up study evaluating FMT to date [18].
The follow-up period, starting either at the beginning of
antibiotic therapy or after FMT treatment, was 90 days. At
that point, patients who had not developed RCDI were
considered to be improved, or ‘cured’ [18]. If patients did not
improve, they could either have severe/fulminant colitis or
RCDI. Patients remained with that condition of health for the
remainder of the 90-day follow-up.
Model variables
Table 1 contains all input parameters for the model, including
probabilities, costs and utilities, along with corresponding
distribution parameters.
Probability of cure from metronidazole ranged from 65 to
85%, with a mean cure rate of 80% [36]. Probability of cure
from vancomycin ranged from 88 to 92%, with a mean cure
rate of 90% [25]. A recent systematic review and meta-analysis
reveals a weighted probability of FMT cure as 91.2% [15]. In
the previously mentioned prospective trial, probability of FMT
cure, defined as no recurrence within the first 90 days after
treatment, was 91% [18]. Similar rates of cure have been
quoted in the literature, ranging from 83% to 100% [15,21].
Probability of developing fulminant colitis, which would be
treated with inpatient medical or surgical treatment, ranged
from 5 to 26%, with a mean probability of 16% [37–40]. We
incorporated mortality from fulminant colitis into the payoff at
the terminal node by using the probability of dying to adjust
the assumed number of days that the patient would live [41].
Importantly, severe and fulminant colitis represent a spectrum
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of disease. Because there is no consensus definition of severe
or fulminant colitis, incidence rates reported in the literature
are all based on different definitions [42–45].
No adverse events, including death, have been reported as a
direct result of FMT in patients without underlying comorbid
conditions [15,21]. Adverse effects of FMT were, therefore,
FIG. 1. Model structure. FMT, faecal microbiota transplantation; RCDI, recurrent Clostridium difficile infection; AE, adverse effects of FMT.
TABLE 1. Model variables
Variable Mean Lower limit Upper limit Distribution References
Probabilities
Primary cure rate: FMT 0.91 0.83 1 Beta [15,18,21]
Primary cure rate: vancomycin 0.90 0.88 0.92 Beta [25]
Primary cure rate: metronidazole 0.80 0.65 0.85 Beta [36]
Fulminant colitis 0.16 0.05 0.27 Beta [25]
Adverse events of FMT 0.0028 0.0017 0.0058 Beta [28]
Death from FMT 0.0003 0 0.0009 Beta [29]
Death from fulminant colitisa 0.347 [41]
Costs
FMT $1086 $815 $1358 Gamma [14,48]
Vancomycinb $1347 $1195 $1499 Gamma [25,47]
Metronidazoleb $57 $43 $72 Gamma [25]
Fulminant colitis $23 717 $17 788 $29 646 Gamma [25] [calculated]
RCDI $2136 $1602 $2670 Gamma [14,25]
Adverse events of FMT $30 009 $16 255 $43 762 Gamma [31] [mean midpoint]
Utilities
Fulminant colitis 0.57 0.32 0.82 Beta [32,33] [midpoint]
RCDI 0.88 0.80 0.90 Beta [32]
Adverse events of FMT 0.15 0.00 0.65 Beta [34]
Cure 1.00 Beta
Death 0 Beta
FMT, faecal microbiota transplantation; RCDI, recurrent Clostridium difficile infection.
aValue incorporated into payoff at terminal node.
bCosts of antibiotic are for a full 10–14-day course. Costs are reported as 2011 US dollars.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 1343–1351
CMI Varier et al. CEA of treatment choices for initial CDI 1345
assumed to be equivalent to aggregate adverse effects of a
diagnostic colonoscopy procedure. Though rare, complica-
tions such as perforation can be quite debilitating to a patient
[28]. Similarly, the probability of death from FMT was assumed
to be equivalent to the probability of death from a colonos-
copy procedure [29], and not related to CDI after the
procedure. Adverse effects of metronidazole were assumed to
be negligible [46], as were the adverse effects of vancomycin,
and were not included in this model.
The values for cost inputs were obtained from the Center
for Medicare and Medicaid Services (CMS) and from previously
published studies. Cost data were adjusted to 2011 US Dollars
using the Consumer Price Index from the US Bureau of Labor
Statistics [30]. The mean cost of a 10–14-day metronidazole
course was $57 (range, $43–72) [25]. The mean cost of a 10–
14-day vancomycin course was $1347 (range, $1195–1499)
[25,47]. The cost of RCDI, $2136 (range, $1602–2670)
included the cost of repeat testing and treatment with another
course using vancomycin taper [14,25]. The mean direct cost
of FMT, including testing, procedure (45378 CPT code) and
facility costs, was $1086 (range, $815–1358) [14,48]. The cost
of colitis ($23 717; range, $17 788–29 646) reflected an
aggregate cost of severe/fulminant colitis, which includes
hospitalization and medical therapy with intravenous metro-
nidazole and vancomycin, as well as probability and costs of
surgery and death [14,25]. The cost of the adverse effects of
FMT was estimated to be equivalent to the cost of perforation
following colonoscopy, as reported in a prior cost study [31].
Currently, no published utility values exist for CDI.
Therefore, as has been done in other cost-effectiveness
analyses of CDI treatment or preventions strategies, we used
estimates of the utility of non-infectious diarrhoea as our
values for the utility of colitis- and RCDI-associated diarrhoea
[32–34]. These utility weights for colitis and RCDI were
applied for a duration of 90-days minus the time treated with
antimicrobial therapy.
Sensitivity analysis
In order to investigate uncertainty in our parameter estimates
and the influence of our base-case assumptions on these
values, we conducted a number of sensitivity analyses. First, in
one-way sensitivity analyses, we varied the value of several key
parameters, including probabilities of cure and costs of
metronidazole, vancomycin and FMT, one at a time. This
allowed us to identify threshold values of the parameters for
which our results changed. In addition, we simultaneously
varied all parameters in a probabilistic sensitivity analysis using
10 000 second-order Monte Carlo simulations. The distribu-
tions for each parameter are shown in Table 1.
Results
The results of the base-case and one-way sensitivity analyses
are shown in Table 2 and Fig. 2(a–c), respectively.
Base case analysis, using the mean value of each parameter,
showed that FMT ($1669, 0.242 QALYs) was more costly and
more effective than metronidazole ($1167, 0.238 QALYs),
yielding an ICER of $124 964/QALY. FMT was dominant (less
expensive and more effective) compared with vancomycin
($1890, 0.241 QALYs). Probability of cure of metronidazole
and FMT, and to a lesser extent their respective associated
costs, had an influence on the model (Fig. 3). One-way
sensitivity analyses showed that metronidazole dominated
both competing strategies if its probability of cure was >90%.
FMT dominated if its costs were <$584, if the cost of
metronidazole was >$559, or if the probability of cure of
metronidazole was <71%.
In a probabilistic sensitivity analysis, varying all parameters
simultaneously, metronidazole was favoured in approximately
55% of model iterations and FMT was favoured in 38% at a
willingness-to-pay threshold of $100 000/QALY (Fig. 4).
Discussion
This study is the first cost-effectiveness analysis investigating
the use of current treatment strategies, as well as the
theoretical use of FMT, for the treatment of initial CDI. Our
results suggest that metronidazole, as the first-line treatment
for CDIs, may be less costly, but that FMT and vancomycin are
more effective. Our model estimated that the extra cost
TABLE 2. Base-casea results. Cost-effectiveness of FMT vs. vancomycin or metronidazole
Strategy Cost ($) IC ($) Effectiveness (QALY) IE (QALY) ICER ($/QALY)
Metronidazole 1167 – 0.238 – –
FMT 1669 503 0.242 0.0040 124 964
Vancomycin 1890 305 0.241 0.0002 Dominated
FMT, faecal microbiota transplantation; QALY, quality-adjusted life year; IC, incremental cost; IE, incremental effectiveness; ICER, incremental cost-effectiveness ratio.
aAnalysis performed using baseline values. Cost values are reported as 2011 US dollars.
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FIG. 2. (a, b, c) Results, one-way sensitivity analysis. (a) Impact of changes in cost of FMT on overall cost per strategy. (b) Impact of changes in
probability of CDI cure with FMT on overall cost per strategy. (c) Impact of changes in probability of CDI cure with FMT on overall effectiveness per
strategy.
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associated with FMT for this increased effectiveness was
$124 964/QALY. Historically, a willingness-to-pay of $50 000/
QALY has been used as a cut-off for new healthcare
interventions [49]. However, a recent study suggests that a
more plausible range may be between $109 000 and
$297 000/QALY [50]. Using these updated willingness-to-pay
thresholds, our estimates suggest that FMT may be considered
cost-effective compared with metronidazole for initial CDI.
It should be noted that, after our analysis was complete, an
economic analysis of FMT by Konijeti et al. [24] was published.
While there were a number of similarities between this
analysis and ours, a key difference is that Konijeti’s analysis
considered FMT via colonoscopy for the first recurrence of
CDI after initial treatment. Our study is different, as it is the
first to evaluate the use of FMT at the initial occurrence of
CDI.
FIG. 3. Tornado diagram, FMT vs.
Metronidazole, ICER.
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We included vancomycin as a possible treatment strategy in
our model because it is recommended for treatment of initial
CDI when metronidazole is not an option by the ACG, AGA
and Infectious Disease Society of America guidelines [5,9,14].
However, our model shows that vancomycin was both more
expensive and less effective than FMT in patients with initial
CDI. We chose not to include additional intervention strat-
egies in our model, such as intravenous immunoglobulin,
probiotics, cholestyramine or fidaxomicin, because there is
little evidence to suggest that these are viable treatment
options for initial CDI [5,10–13,51].
Several important limitations of our analysis, mostly related
to assumptions made in our model, are worth noting. First, this
study incorporated data from reports evaluating adult subjects
without other serious comorbid conditions such as end-stage
renal disease or inflammatory bowel disease (IBD). Risks of the
strategies that we compared may differ in patients with
comorbid conditions. For instance, though currently deemed
relatively safe, there has been a case report of bacteraemia
following FMT in a patient with IBD [52–54]. Because
colonoscopy would not be performed in patients with
fulminant colitis, the model excluded such patients. Given
the risks of performing colonoscopy in these patients, if FMT
were to be considered in patients with fulminant colitis or
signs of toxic megacolon, nasoenteral administration would be
preferred.
Second, we assumed that patients receive FMT via colo-
noscopy, and our model inputs reflect the probability of
success of FMT using this technique as reported in the
literature for RCDI. Though previously published data suggest
higher success rates of FMT via colonoscopy compared with
other methods, newer technologies, such as faecal transplant
capsules or using frozen inoculum, may have comparable
success rates of FMT for RCDI [15,20,21,23,55,56]. If the
capsule method, or another, is indeed equivocal, alternative
routes for FMT may prove even less costly than the values
used in this model, with a presumed similar safety profile.
While we did not explicitly model alternative administration
routes for FMT, we did explore a wide range of values for the
cost and efficacy of FMT in one-way sensitivity analyses. These
sensitivity analyses can serve to indicate how the results of our
model might change under different FMT techniques.
Third, we also assumed that all patients entering the model
received outpatient treatment, in order to be consistent with
the studies from which we drew our parameters for the
effectiveness of FMT. Treatment may not always occur in an
outpatient setting, as patients can also be admitted to the
hospital with moderate CDI, or can develop CDI while
hospitalized, and might still be considered as candidates for
FMT. Further, although we did not model an inpatient
population, we would expect similar results for both costs
and QALYs. As future studies are conducted to evaluate the
effectiveness of FMT in an inpatient setting, new economic
models should be constructed to incorporate these new
findings.
Additionally, CDI severity was not incorporated into this
model, though it is known that drug choices and cure rates are
known to depend on disease severity. While including various
levels of disease severity in our model would have been ideal,
this was not possible due to a paucity of respective data with
FMT cure rates stratified to disease severity. This is an area
that would benefit from future studies. Subsequent economic
analyses could expand on the model presented here to
examine how the cost-effectiveness of FMT varies by severity
of CDI.
The data used for parameters in our model came from
studies of varying quality. Given the lack of existing studies
examining FMT from which to gather inputs, results may be
affected by data from future studies. For example, because no
data exist on the efficacy of FMT for initial CDI, we assumed
that FMT for initial CDI would be as effective as when used for
RCDI. To temper these assumptions, we chose a conservative
model design by underestimating some of the parameters
associated with metronidazole and vancomycin. The most
commonly reported side-effects of these two non-absorbed
medications are non-specific or mild gastrointestinal symp-
toms such as nausea and abdominal pain [57]. Therefore, we
decided not to incorporate adverse effects of metronidazole
and vancomycin and their respective associated costs. Addi-
tionally, cure rates of metronidazole and vancomycin that are
reported in the literature are defined by various outcomes.
We chose to overestimate the respective cure rates of these
medications in order to maintain the conservative design of
the model.
Despite these issues, our model can provide useful infor-
mation about the potential economic trade-offs associated
with the FMT intervention compared with treatment with
metronidazole, and alternatively vancomycin, for initial CDI.
The purpose of this analysis is to provide an initial look at the
cost-effectiveness of these strategies in the treatment of initial
CDI. Our results provide support for future trials to
demonstrate the efficacy and safety of FMT therapy. In
addition, future studies should be used to understand the
role of FMT in initial and earlier recurrences of CDI, and to
analyse different routes of FMT administration.
We chose to perform this study from the third-party payer
perspective, using data from the United States’ CMS as our
point of reference. We acknowledge that the results may differ
with consideration of the societal perspective, for instance,
which would include additional direct costs such as patient
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transportation and out-of-pocket costs, as well as indirect
costs such as the patient and/or caregiver missing work and
other time costs. Future prospective studies are needed to
confirm the results of our analysis.
In conclusion, the results of our decision analytic computer
simulation suggest that FMT may lead to improved outcomes
in patients with initial CDI compared with standard first-line
treatments such as metronidazole and vancomycin. These
improved outcomes came at a higher cost compared with
metronidazole and at a lower cost compared with vancomycin.
This information provides makers of healthcare policy with
additional insights when considering treatments for CDI in
today’s changing healthcare economic landscape.
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